Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000799042 | SCV000938689 | likely benign | Tuberous sclerosis 2 | 2024-07-22 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000799042 | SCV001481182 | uncertain significance | Tuberous sclerosis 2 | 2020-06-05 | criteria provided, single submitter | clinical testing | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. |
Genome- |
RCV000799042 | SCV002039698 | likely benign | Tuberous sclerosis 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002440661 | SCV002747741 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-10-03 | criteria provided, single submitter | clinical testing | The p.P961L variant (also known as c.2882C>T), located in coding exon 25 of the TSC2 gene, results from a C to T substitution at nucleotide position 2882. The proline at codon 961 is replaced by leucine, an amino acid with similar properties. This alteration was identified in 1 of 374 patients with clinically suspected TSC undergoing genetic testing within the TSC1 and TSC2 genes (Meng Y et al. J Hum Genet, 2021 Mar;66:227-236). This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Gene |
RCV003117590 | SCV003798742 | uncertain significance | not provided | 2022-08-03 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |